Opinion|Videos|February 9, 2026
How Subcutaneous Amivantamab Fits into EGFR-Mutated NSCLC Management
Author(s)Narjust Florez, MD
PALOMA-3: subcutaneous amivantamab matches IV levels, slashes infusion reactions and steroids, and shortens clinic time.
Advertisement
Episodes in this series
Narjust Florez, MD, discusses how amivantamab and hyaluronidase-lpuj (Rybrevant Faspro; subcutaneous amivantamab) could be incorporated into routine care for patients with EGFR-mutated non–small cell lung cancer (NSCLC). Florez outlines practical considerations, including time in chair, resource utilization, and patient convenience, that may influence adoption in oncology practice. She also considers how this formulation could ultimately impact the use of the intravenous formulation.
Advertisement
Related to this article
A Dana-Farber study identified an RNA surveillance defect that fuels melanoma through endogenous retroviral RNA.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
Updated COMMANDS data showed durable RBC transfusion independence and a positive overall survival trend with luspatercept in lower-risk MDS.
Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.
Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.
Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.
Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
Advertisement
Advertisement
Trending on OncLive
1
June’s GI Rewind: CRC, Gastric Cancer See Several “Firsts” With FDA Review of Adjuvant IO, Global Approval of BRAF-Targeted and CAR T-Cell Therapies
2
Dr Orloff on Key Findings From the Phase 2/3 OptimUM-02 Trial in Uveal Melanoma
3
Namodenoson Meets Safety End Point in PDAC, Shows Durable Survival Outcomes Pretreated Subgroup
4
Belantamab Mafodotin Yields Sustained MRD Negativity in R/R Myeloma
5